The second-line antitubercular drugs thiacetazone (TAZ) and ethionamide (ETA) are bioactivated by the mycobacterial enzyme EtaA. We report here that human FMO2.1, which is expressed predominantly in the lung, catalyzes oxygenation of TAZ. The metabolites generated, the sulfenic acid, sulfinic acid and carbodiimide derivatives, are the same as those produced by EtaA and by human FMO1 and FMO3. Two of the metabolites, the sulfenic acid and carbodiimide, are known to be harmful to mammalian cells. FMO2.1 also catalyzes oxygenation of ETA, producing the S-oxide.
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Pulmonary tuberculosis (TB) is a serious respiratory disease caused by the opportunistic bacterium Mycobacterium tuberculosis. The World Health Organization estimated 9.2 million new cases of TB infection worldwide in 2006, of which 31% were in Africa. The appearance of strains of M. tuberculosis that are resistant to more than one first-line antitubercular drug has required the use of second-line drugs (Peloquin, 1993) such as the thiourea thiacetazaone (TAZ, 4'-formylacetanilide thiosemicarbazone) and the thioamide ethionamide (ETA, 2-ethylpyridine-4-carbothioamide). TAZ has been widely used in the developing world (Brown, 1992) .
Although an effective treatment for multidrug-resistant TB, it can produce adverse effects such as liver toxicity, gastrointestinal disturbances and life-threatening skin reactions, particularly in HIV patients (Teklu, 1976; Brown, 1992; Peloquin, 1993; Ipuge et al., 1995) , and, consequently, its use has been discontinued in several countries (Brown, 1992) . ETA continues to be prescribed in both developed and developing countries.
Both TAZ and ETA are prodrugs that are converted to their active forms by the mycobacterial enzyme EtaA (Baulard et al., 2000; DeBarber et al., 2000; Qian and Ortiz de Montellano, 2006) , a flavin-containing monooxygenase (Vannelli et al., 2002) . EtaA activates TAZ by two sequential oxidation steps to form a sulfinic acid and a carbodiimide, via a postulated sulfenic acid intermediate (Qian and Ortiz de Montellano, 2006) . TAZ treatment affects mycolic acid biogenesis in mycobacteria (Dover et al., 2007; Alahari et al., 2007) , and this may be the mechanism by which the drug exerts its antimicrobial effect.
The flavin-contaning monooxygenases (FMOs; EC 1.14.13.8) of mammals catalyze the oxidative metabolism of numerous xenobiotics, including pesticides,
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fertilizers and therapeutic drugs (Krueger and Williams, 2005; Cashman and Zhang, 2006; Phillips et al., 2007; Phillips and Shephard, 2008) . Humans express five functional FMOs, FMOs 1-5 (Phillips et al., 1995; Hernandez et al., 2004) . FMO1, FMO2 and FMO3 can bioactivate thiourea-based drugs (Smith and Crespi, 2002; Henderson et al., 2004; Onderwater et al., 2006) and FMO1 and FMO3 have been shown to catalyze oxygenation of TAZ in vitro, forming the same products as EtaA (Qian and Ortiz de Montellano, 2006) .
A genetic polymorphism of the FMO2 gene, g.23238C>T (Q472X), gives rise to an allele, FMO2*2, which encodes a truncated, non-functional protein (FMO2.2) (Dolphin et al., 1998) . Essentially all Europeans and Asians are homozygous for
Isolation of microsomal membranes. Sf9 cells were harvested and resuspended in HEPES buffer (0.154 M KCl, 10 mM HEPES (pH 7.4), 1 mM EDTA, 20% (v/v) glycerol). Cells were lysed by three 12-s bursts of sonication on ice. Cell lysates were centrifuged at 1000 x g for 10 min at 4 ˚C. The resulting supernatant was centrifuged at 100,000 x g for 1 h at 4˚C. The pellet was resuspended in HEPES buffer by hand, using a glass-glass homogenizer placed on ice, and stored in aliquots at -80 ˚C. Protein concentration was determined using the method of Lowry (D C Protein Assay kit, Bio-Rad, Hercules, CA) and bovine serum albumin (Bio-Rad, Hercules, CA) as a standard.
Quantification of FMOs.
Antibodies to FMO1 and FMO2 and FMO3 were a gift from Dr. R. Philpot. Heterologously expressed FMOs were quantified by western blotting essentially as described previously (Dolphin et al., 1997; Dolphin et al.,
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(data not shown). The results corresponded well with those obtained by western blotting, indicating that there was no appreciable difference in cross-reactivity among the antibodies.
Enzyme incubations with TAZ or ETA. Sf9 insect cell microsomes containing heterologously expressed human FMO1, FMO2.1 or FMO3 (at a final concentration of 500 nM) or purified EtaA (1 µM final concentration) were incubated with TAZ (100 µM final concentration) at 37 ˚C for 90 min in the buffer described previously (Qian and Ortiz de Montellano, 2006) . Reactions were initiated by the addition of enzyme. Reactions were stopped by addition of an equal volume of ice-cold CH 3 CN.
Mixtures were centrifuged at 10,000 x g for 5 min at 4 ˚C and analysed by HPLC as described below.
Sf9 insect cell microsomes containing heterologously expressed human FMO2.1 were incubated with ETA (final concentration 100 µM) for 60 min as described previously (Qian and Ortiz de Montellano, 2006) . Reactions were analysed by Liquid Chromatography-Mass Spectroscopy (LC-MS) as described below.
HPLC
The supernatants were diluted to a final concentration of 5% CH 3 CN and then analysed by HPLC on a reverse-phase C18 column (Waters, 3.5 µm particle size, 4.6 Enzyme-catalyzed oxidation of TAZ was monitored by measuring the rate of decrease in the absorbance of TAZ at 328 nm, using a dual-beam spectrophotometer (Varian Cary 100 (kinetics module)). The pH optima for human FMOs and EtaA were determined using the following reaction buffers: 0.1 mM potassium phosphate (pH 7.5), 1 mM EDTA; 0.1 M Tris-HCl (pH 8.5) 1mM EDTA and 0.1 M Tricine-OH (pH 9.5), 1 mM EDTA. Immediately before use buffers were aerated at 37 ˚C for 30 min in a shaking water bath. Assays were performed in a volume of 1 mL in reaction buffer containing 0.1 mM NADPH and either Sf9 cell microsomes containing human FMO1 (320 nM), FMO2.1 (5 nM) or FMO3 (230 nM), or purified EtaA (1 µM).
Reaction mixtures were allowed to equilibrate for 1 min at 37 ˚C. Reactions were initiated by the addition of TAZ in DMSO (to a final TAZ concentration of 10 µM) to the sample cuvette and DMSO to the reference cuvette. Initial rates were recorded between 1 and 5 min.
For determination of kinetic parameters assays were performed on triplicate preparations of enzymes at concentrations of TAZ ranging from 1 to 20 µM. The final organic solvent concentration was held at 0.1% (v/v). Assays were carried out in triplicate as described above in the optimum pH buffer for each enzyme: pH8.5 for FMO1 and FMO3 and 9.5 for FMO2.1 and EtaA. with an equal volume of ice-cold CH 3 CN. ETA was added as an internal standard at a final concentration of 100 µM (in DMSO) and mixtures were prepared for HPLC analysis as described above. A standard curve was generated by plotting the ratio of the integrated HPLC peak areas of TAZ and ETA (from the sample set without added enzyme), against the range of TAZ concentrations used. The ratio of the integrated HPLC peak areas of TAZ and ETA, in the sample set with added enzyme, was calculated and the amount of unmetabolized TAZ determined from the standard curve. This value was subtracted from the input concentration of TAZ to calculate the amount of TAZ metabolized by the enzyme. V max , K M and k cat were determined as above.
Enzyme incubations with methimazole. Sf9 insect cell microsomes containing heterologously expressed human FMO1, FMO2.1 or FMO3 were assayed for activity towards methimazole by the method of Dixit and Roche (Dixit and Roche, 1984) as described previously (Dolphin et al., 1998) . Assays for FMO1 and FMO3 activity were carried out at pH 8.5 and those for FMO2.1 at pH 9.5. This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1) . No products were observed when TAZ was incubated with microsomes isolated from non-infected Sf9 cells or when NADPH was omitted (results not shown). UV spectral analysis of the metabolites (Fig. 2) showed that M1 had a maximal absorption peak at 325 nm and a smaller peak at approximately 230 nm. M2 had a similar spectrum, with peaks at 320 and 220 nm. The absorption spectrum of M3 exhibited a main peak at 295 nm and a secondary peak at 220 nm.
To identify the three metabolites, M1, M2, and M3, formed from TAZ by the action of human FMO2.1, they were analysed by LC-MS. The mass spectrum of M1 had a molecular ion [M + H] + at m/z 269.07, with fragment ions at m/z 205.14 and 163.12 (Fig. 3a) . The mass of the molecular ion of M1 is 32 atomic mass units more than that of the molecular ion of TAZ (237), suggesting a structure in which TAZ has incorporated two oxygen atoms ( Fig. 3a) and hence supports identification of the metabolite as the sulfinic acid derivative. The mass spectrum of M2 had a molecular ion [M + H] + at m/z 253, with fragment ions at m/z 235 and 193 (Fig. 3b) . The mass of the molecular ion of M2 is in accord with a structure in which TAZ has incorporated a single oxygen atom, and thus supports identification of M2 as the monooxygenated, sulfenic acid derivative. The metabolite M3 has a molecular ion [M + H] + at m/z 203.13, which suggests that it is the carbodiimide generated by elimination from M2 of the oxidized sulfur atom (Fig. 3c) (Fig. 5b) . The mass of the molecular ion of P1 is 16 atomic mass units more than that of the molecular ion of ETA (166), suggesting a structure in which ETA has incorporated one oxygen atom (Fig. 5b) . This supports identification of P1 as the S-oxide of ETA. The retention time and mass spectrum of P1 are identical to those of authentic ETA S-oxide (Vannelli et al., 2002) , therefore (Table 1) .
Consequently, k cat /K M (the specificity constant) for TAZ is much higher for human FMO2.1 than for the other three enzymes (Table 1) . Very similar kinetic parameters for FMO2.1-catalyzed TAZ oxygenation were obtained through the use of an HPLCbased assay, thus validating the spectrophotometric assay (data not shown).
As a comparison, we determined kinetic parameters for FMO1-, FMO2.1-and FMO3-catalyzed oxygenation of methimazole, a prototypic substrate for FMOs (Table 1 ). The k cat of each enzyme was similar for TAZ and methimazole. However, for FMO2.1 the K M for methimazole was 100-fold greater than that for TAZ.
Consequently, for methimazole oxygenation, the k cat /K M of FMO2.1 is considerably less than that of FMO1 and slightly less than that of FMO3.
This article has not been copyedited and formatted. The final version may differ from this version. However, the second product identified by these authors, the amide of ETA, was not detected in our study.
Our kinetic analyses reveal that k cat /K M (the specificity constant) for FMO2.1-catalyzed TAZ oxygenation is much higher than that of FMO1, FMO3 or the mycobacterial enzyme EtaA, indicating that FMO2.1 is more effective in catalyzing TAZ oxygenation than are the other three enzymes. In contrast, FMO2.1 is less effective than FMO1 or FMO3 in catalyzing the oxygenation of methimazole.
Although kinetic analyses were done at the pH optimum for each enzyme, even at a more physiological pH (7.5), as shown in Fig. 7, FMO2 .1 is the most effective of the This article has not been copyedited and formatted. The final version may differ from this version. (Lawton et al., 1991) .
Spectrophotometric and kinetic studies indicate that the rate-limiting step for FMO-catalyzed reactions occurs after substrate oxygenation (reviewed in Ziegler, 2002) and thus is independent of oxidizable substrate. Consequently, for a particular FMO, the value of k cat would be expected to be similar for all its substrates. Although our results conform to this expectation, they indicate that the k cat of human FMO2.1 is higher than that of FMO1 or FMO3, suggesting that FMO2.1 is more effective in catalyzing the rate-limiting step of the reaction, the elimination of H 2 O, than is either of the other two FMOs investigated.
Substrate oxygenation by FMOs is usually a detoxification process. However, in the case of thioureas the products of FMO-catalyzed oxygenation are typically more toxic than the parent compound (Smith and Crespi, 2002; Henderson et al., 2004; Onderwater et al., 2004 Onderwater et al., , 2006 . TAZ sulfenic acid is an electrophile that can react with glutathione (GSH) (Qian and Ortiz de Montellano, 2006) to regenerate the parent compound and convert GSH to its oxidized form (GSSG). In the presence of This article has not been copyedited and formatted. The final version may differ from this version. GSH reductase, a redox cycle may be established that depletes GSH, thus causing oxidative stress and cellular injury (Krieter et al., 1984; Henderson et al., 2004; Onderwater et al., 2004) . Sulfenic acid metabolites of thioureas can react covalently with other thiol-containing molecules, such as cysteine residues in proteins, and thus directly perturb protein function (Decker and Doerge, 1992) . The TAZ carbodiimide, too, has the potential to form covalent products with cysteine residues in proteins.
Thus, each of the human FMOs that we have investigated, FMO1, FMO2.1, FMO3, is able to catalyze oxygenation of TAZ, producing metabolites that are known to be harmful to mammalian cells.
The FMO-catalyzed production of TAZ metabolites that are known to be harmful to mammalian cells may be the basis for the adverse clinical reactions associated with this drug (Teklu, 1976; Brown, 1992; Peloquin, 1993; Ipuge et al., 1995) . This is supported by the fact that all of the adverse effects associated with TAZ occur in tissues in which FMOs are expressed: hepatotoxicity, FMO3 in the liver (Dolphin et al., 1996; Hernandez et al., 2004) ; gastrointestinal problems, FMO1 in the small intestine (Yeung et al., 2000) ; and skin rashes, FMO1 and FMO3 in skin (Janmohamed et al., 2001 ).
Human FMO1 and FMO3 are expressed primarily in the kidney and liver, respectively, and thus may contribute to the extra-pulmonary metabolism of TAZ.
FMO1 displays interindividual variation in its expression (Yeung et al., 2000; Koukouritaki et al., 2002) and several nonsynonymous polymorphic variants of FMO3 have been identified (reviewed in Phillips et al., 2007; Phillips and Shephard, 2008) ) one of which, L360P, increases enzyme activity (Lattard et al., 2003) , whereas others, such as E158K and E308G, when present together in cis, decrease enzyme activity (reviewed in Phillips et al., 2007; Phillips and Shephard, 2008) . Promoter This article has not been copyedited and formatted. The final version may differ from this version. 
